Apredica Acquires Cellumen | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Contract research organization Apredica announced today that it has acquired the intellectual property and related assets of Cellumen for an undisclosed sum.

The acquisition provides Apredica with Cellumen's Cellular Systems Biology and high-content toxicology services and technologies. Specifically, Watertown, Mass.-based Apredica said that the deal will "significantly strengthen" the firm's high-content toxicology offerings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.